NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 184 planned
- Started
- 12 Apr 2021
- Primary completion
- 30 Sep 2025
- Arms
- Tislelizumab (Cohort-3 PD1-high)
- Results
- None posted
- 17 Mar 2021: Trial registered
- 12 Apr 2021: Trial started